Reflex UroVysion testing in suspicious urine cytology cases
Open Access
- 29 January 2009
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 117 (1), 7-14
- https://doi.org/10.1002/cncy.20016
Abstract
BACKGROUND: UroVysion is a US Food and Drug Administration–approved fluorescence in situ hybridization (FISH) probe set for use in the detection of recurrent urothelial carcinoma and in patients with hematuria. The objective of the current study was to evaluate the usefulness of UroVysion as a reflex test in patients with a suspicious urine cytology diagnosis. The rationale was that a more aggressive workup might be indicated in patients with a suspicious cytology diagnosis and positive UroVysion test. METHODS: The study population included 161 urine specimens diagnosed as suspicious over a period of 12 months. The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (NPV) were calculated based on the histologic and cystoscopic correlation. RESULTS: The results using the reporting criteria suggested by the manufacturer demonstrated a sensitivity of 68.3%, a specificity of 39.7%, a PPV of 56.8%, and a NPV of 51.9%. The results using the presence of any cytogenetic abnormality as a positive FISH test demonstrated a sensitivity of 82.9%, a specificity of 21.7%, a PPV of 54.8%, and an NPV of 51.7%. CONCLUSIONS: A negative UroVysion test did not rule out the presence of low-grade or high-grade urothelial carcinoma in urine specimens diagnosed as suspicious. The use of less strict criteria dramatically increased the sensitivity of UroVysion FISH; however, there was a marked decrease in specificity noted. The results in this current study appear to indicate that a more aggressive workup of patients with a suspicious cytology, positive UroVysion result, and negative cystoscopic evaluation is not currently justified. Cancer (Cancer Cytopathol) 2009. © 2009 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Reflex UroVysion Testing of Bladder Cancer Surveillance Patients With Equivocal or Negative Urine CytologyAmerican Journal of Clinical Pathology, 2007
- Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinomaDiagnostic Cytopathology, 2003
- Clinical Evaluation of a Multi-target Fluorescent in Situ Hybridization Assay for Detection of Bladder CancerJournal of Urology, 2002
- A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in UrineJournal of Urology, 2002
- Multiprobe FISH for Enhanced Detection of Bladder Cancer in Voided Urine Specimens and Bladder WashingsAmerican Journal of Clinical Pathology, 2001
- A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, 2000
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000
- Origins and clinical implications of aneuploidy in early bladder cancerCytometry, 1995
- The clinical value of urinary cytology: 12 years of experience with 615 patients.Journal of Clinical Pathology, 1995
- Intratumoral Heterogeneity in DNA Ploidy of Bladder CarcinomasOncology, 1992